Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 28 | 2020 | 561 | 7.120 |
Why?
|
| Carcinoma, Squamous Cell | 19 | 2021 | 629 | 5.020 |
Why?
|
| Salivary Gland Neoplasms | 8 | 2021 | 40 | 4.230 |
Why?
|
| SEER Program | 23 | 2019 | 153 | 3.560 |
Why?
|
| Melanoma | 11 | 2018 | 335 | 3.020 |
Why?
|
| Parotid Neoplasms | 8 | 2020 | 49 | 2.830 |
Why?
|
| Neoplasm Staging | 26 | 2021 | 800 | 2.620 |
Why?
|
| Skin Neoplasms | 9 | 2018 | 375 | 2.180 |
Why?
|
| Prognosis | 26 | 2021 | 2093 | 2.030 |
Why?
|
| Survival Rate | 19 | 2021 | 1056 | 2.010 |
Why?
|
| Carcinoma | 5 | 2019 | 215 | 1.910 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 4848 | 1.870 |
Why?
|
| Mouth Neoplasms | 5 | 2021 | 206 | 1.750 |
Why?
|
| Aged | 54 | 2021 | 14862 | 1.690 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2014 | 94 | 1.660 |
Why?
|
| Middle Aged | 64 | 2021 | 21147 | 1.620 |
Why?
|
| Thyroid Neoplasms | 4 | 2014 | 68 | 1.600 |
Why?
|
| Retrospective Studies | 41 | 2021 | 7277 | 1.570 |
Why?
|
| Sentinel Lymph Node Biopsy | 9 | 2015 | 53 | 1.540 |
Why?
|
| Carcinoma, Merkel Cell | 4 | 2014 | 12 | 1.510 |
Why?
|
| Carcinoma, Basosquamous | 3 | 2014 | 4 | 1.410 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2020 | 14 | 1.330 |
Why?
|
| Proportional Hazards Models | 16 | 2018 | 792 | 1.310 |
Why?
|
| Male | 67 | 2021 | 37321 | 1.280 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 446 | 1.270 |
Why?
|
| Female | 65 | 2021 | 38074 | 1.260 |
Why?
|
| Disease-Free Survival | 13 | 2017 | 349 | 1.240 |
Why?
|
| Adult | 44 | 2021 | 21403 | 1.190 |
Why?
|
| Humans | 80 | 2021 | 68618 | 1.120 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2017 | 536 | 1.100 |
Why?
|
| Combined Modality Therapy | 11 | 2021 | 951 | 1.090 |
Why?
|
| Survival Analysis | 13 | 2021 | 714 | 1.070 |
Why?
|
| Laryngeal Neoplasms | 3 | 2017 | 47 | 1.040 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 91 | 1.030 |
Why?
|
| Age Factors | 10 | 2014 | 1864 | 1.030 |
Why?
|
| Young Adult | 18 | 2021 | 5717 | 0.960 |
Why?
|
| Carcinoma, Acinar Cell | 3 | 2020 | 14 | 0.950 |
Why?
|
| Adenocarcinoma | 3 | 2016 | 475 | 0.940 |
Why?
|
| Facial Neoplasms | 2 | 2014 | 10 | 0.940 |
Why?
|
| Adolescent | 22 | 2021 | 8912 | 0.940 |
Why?
|
| Registries | 5 | 2018 | 733 | 0.910 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2014 | 13 | 0.900 |
Why?
|
| Lymph Nodes | 4 | 2014 | 258 | 0.880 |
Why?
|
| Thyroidectomy | 5 | 2012 | 31 | 0.880 |
Why?
|
| Lymphatic Metastasis | 7 | 2016 | 274 | 0.880 |
Why?
|
| Multivariate Analysis | 11 | 2018 | 1046 | 0.840 |
Why?
|
| Thyroid Diseases | 3 | 2011 | 33 | 0.820 |
Why?
|
| United States | 16 | 2019 | 7367 | 0.790 |
Why?
|
| Sleep Apnea, Obstructive | 2 | 2020 | 142 | 0.760 |
Why?
|
| Child | 14 | 2021 | 6405 | 0.750 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 47 | 0.730 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2020 | 12 | 0.710 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2020 | 40 | 0.690 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2019 | 10 | 0.690 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 12 | 0.680 |
Why?
|
| Incidence | 6 | 2021 | 1603 | 0.610 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2017 | 6 | 0.600 |
Why?
|
| Sex Factors | 6 | 2021 | 1266 | 0.570 |
Why?
|
| Salivary Glands | 2 | 2018 | 52 | 0.570 |
Why?
|
| Treatment Outcome | 19 | 2021 | 7029 | 0.570 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2016 | 10 | 0.570 |
Why?
|
| Cricoid Cartilage | 1 | 2016 | 10 | 0.560 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 26 | 0.560 |
Why?
|
| Carcinoma, Large Cell | 1 | 2016 | 6 | 0.560 |
Why?
|
| Databases, Factual | 7 | 2018 | 622 | 0.560 |
Why?
|
| Neoplasm Invasiveness | 6 | 2018 | 369 | 0.560 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2016 | 18 | 0.540 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 100 | 0.540 |
Why?
|
| Carcinoma, Small Cell | 1 | 2016 | 53 | 0.530 |
Why?
|
| Child, Preschool | 8 | 2018 | 3187 | 0.530 |
Why?
|
| Quality of Life | 3 | 2020 | 1515 | 0.510 |
Why?
|
| Photochemotherapy | 1 | 2015 | 59 | 0.480 |
Why?
|
| Risk Assessment | 10 | 2018 | 2007 | 0.480 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 371 | 0.480 |
Why?
|
| Tracheotomy | 1 | 2014 | 17 | 0.470 |
Why?
|
| Parotid Gland | 3 | 2021 | 33 | 0.460 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 84 | 0.450 |
Why?
|
| Adenocarcinoma, Sebaceous | 1 | 2013 | 2 | 0.450 |
Why?
|
| Radiosurgery | 1 | 2014 | 66 | 0.450 |
Why?
|
| Liposarcoma | 1 | 2013 | 13 | 0.450 |
Why?
|
| Uvula | 1 | 2013 | 5 | 0.440 |
Why?
|
| Cohort Studies | 7 | 2021 | 2358 | 0.440 |
Why?
|
| Plasmacytoma | 1 | 2013 | 15 | 0.440 |
Why?
|
| Cause of Death | 1 | 2013 | 241 | 0.420 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2017 | 125 | 0.420 |
Why?
|
| Critical Illness | 1 | 2014 | 191 | 0.410 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2012 | 2 | 0.410 |
Why?
|
| Tonsillar Neoplasms | 1 | 2012 | 7 | 0.410 |
Why?
|
| Osteoradionecrosis | 1 | 2012 | 7 | 0.410 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 3259 | 0.400 |
Why?
|
| Sarcoma | 1 | 2012 | 70 | 0.400 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 54 | 0.400 |
Why?
|
| Spinal Diseases | 1 | 2012 | 53 | 0.390 |
Why?
|
| Video-Assisted Surgery | 1 | 2010 | 6 | 0.380 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2010 | 19 | 0.370 |
Why?
|
| Analysis of Variance | 4 | 2013 | 1040 | 0.350 |
Why?
|
| Carcinoma, Papillary | 3 | 2014 | 35 | 0.320 |
Why?
|
| Laryngectomy | 3 | 2017 | 30 | 0.320 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2021 | 62 | 0.320 |
Why?
|
| Risk Factors | 5 | 2021 | 5731 | 0.320 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 306 | 0.280 |
Why?
|
| Gastroesophageal Reflux | 2 | 2006 | 318 | 0.280 |
Why?
|
| Sulfoxides | 1 | 2006 | 16 | 0.280 |
Why?
|
| Obesity | 1 | 2014 | 1076 | 0.280 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 1070 | 0.280 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 47 | 0.270 |
Why?
|
| Omeprazole | 1 | 2006 | 53 | 0.270 |
Why?
|
| Microcirculation | 1 | 2006 | 77 | 0.270 |
Why?
|
| Proton Pump Inhibitors | 1 | 2006 | 91 | 0.260 |
Why?
|
| Benzimidazoles | 1 | 2006 | 128 | 0.260 |
Why?
|
| Postoperative Complications | 4 | 2021 | 1615 | 0.250 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 183 | 0.240 |
Why?
|
| Cheek | 2 | 2014 | 11 | 0.240 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2004 | 9 | 0.240 |
Why?
|
| Lymphatic Diseases | 1 | 2004 | 27 | 0.230 |
Why?
|
| Prospective Studies | 8 | 2021 | 3705 | 0.230 |
Why?
|
| Time Factors | 6 | 2020 | 4655 | 0.230 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 111 | 0.230 |
Why?
|
| Infant | 4 | 2014 | 2891 | 0.220 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1174 | 0.200 |
Why?
|
| Regression Analysis | 2 | 2015 | 737 | 0.200 |
Why?
|
| Zenker Diverticulum | 1 | 2021 | 7 | 0.200 |
Why?
|
| Myotomy | 1 | 2021 | 14 | 0.190 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2018 | 85 | 0.190 |
Why?
|
| Pharyngeal Diseases | 1 | 2021 | 21 | 0.190 |
Why?
|
| Parotitis | 1 | 2021 | 7 | 0.190 |
Why?
|
| Otolaryngologists | 1 | 2021 | 5 | 0.190 |
Why?
|
| Scapula | 1 | 2021 | 36 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2018 | 2324 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 87 | 0.190 |
Why?
|
| Cervical Plexus | 1 | 2020 | 2 | 0.190 |
Why?
|
| Length of Stay | 4 | 2021 | 780 | 0.190 |
Why?
|
| Case-Control Studies | 3 | 2014 | 1553 | 0.180 |
Why?
|
| Free Tissue Flaps | 1 | 2021 | 67 | 0.180 |
Why?
|
| Glossectomy | 1 | 2020 | 9 | 0.180 |
Why?
|
| Body Image | 2 | 2020 | 100 | 0.180 |
Why?
|
| Physician's Role | 1 | 2021 | 116 | 0.180 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2020 | 24 | 0.180 |
Why?
|
| Robotic Surgical Procedures | 1 | 2020 | 49 | 0.170 |
Why?
|
| Rare Diseases | 1 | 2019 | 41 | 0.170 |
Why?
|
| Parathyroidectomy | 4 | 2006 | 45 | 0.170 |
Why?
|
| Salivary Gland Calculi | 1 | 2018 | 4 | 0.160 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1999 | 48 | 0.160 |
Why?
|
| Endoscopes | 1 | 2018 | 36 | 0.160 |
Why?
|
| Airway Obstruction | 1 | 1999 | 49 | 0.160 |
Why?
|
| Mouth | 2 | 2020 | 64 | 0.160 |
Why?
|
| Travel | 1 | 2018 | 38 | 0.150 |
Why?
|
| Oxygen | 1 | 2020 | 386 | 0.150 |
Why?
|
| Health Services | 1 | 2018 | 87 | 0.150 |
Why?
|
| Enteral Nutrition | 1 | 1999 | 157 | 0.150 |
Why?
|
| Morbidity | 1 | 2017 | 130 | 0.150 |
Why?
|
| Sublingual Gland Neoplasms | 1 | 2016 | 1 | 0.140 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2016 | 4 | 0.140 |
Why?
|
| Hyperparathyroidism | 3 | 2006 | 40 | 0.140 |
Why?
|
| Radiopharmaceuticals | 3 | 2006 | 114 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 955 | 0.140 |
Why?
|
| Biopsy, Needle | 2 | 2014 | 191 | 0.130 |
Why?
|
| Comorbidity | 2 | 2017 | 1426 | 0.130 |
Why?
|
| Endoscopy | 1 | 2018 | 464 | 0.130 |
Why?
|
| Orbital Neoplasms | 1 | 2014 | 21 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2017 | 287 | 0.120 |
Why?
|
| Patient Selection | 1 | 2018 | 592 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1753 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1140 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2014 | 129 | 0.120 |
Why?
|
| Nose Neoplasms | 1 | 2014 | 25 | 0.110 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 51 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2014 | 150 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2014 | 138 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2800 | 0.110 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 504 | 0.110 |
Why?
|
| Ear Cartilage | 1 | 2013 | 1 | 0.110 |
Why?
|
| Organ Sparing Treatments | 1 | 2013 | 3 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2013 | 242 | 0.110 |
Why?
|
| Ear, External | 1 | 2013 | 14 | 0.110 |
Why?
|
| Ear Neoplasms | 1 | 2013 | 13 | 0.110 |
Why?
|
| Logistic Models | 2 | 2017 | 1420 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 772 | 0.100 |
Why?
|
| Radiotherapy Dosage | 1 | 2012 | 125 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2014 | 344 | 0.100 |
Why?
|
| Esophagus | 2 | 2006 | 303 | 0.100 |
Why?
|
| Electrosurgery | 1 | 2010 | 15 | 0.090 |
Why?
|
| Sciatic Nerve | 1 | 2010 | 26 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 546 | 0.090 |
Why?
|
| Thyroid Nodule | 1 | 2010 | 15 | 0.090 |
Why?
|
| Facial Paralysis | 1 | 2010 | 25 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 867 | 0.090 |
Why?
|
| Radionuclide Imaging | 3 | 2006 | 166 | 0.090 |
Why?
|
| Technetium Tc 99m Sestamibi | 2 | 2006 | 24 | 0.080 |
Why?
|
| Biopsy | 2 | 2014 | 540 | 0.080 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 508 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 1465 | 0.080 |
Why?
|
| Methylene Blue | 1 | 2006 | 16 | 0.070 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2006 | 16 | 0.070 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 23 | 0.070 |
Why?
|
| Esophageal pH Monitoring | 1 | 2006 | 27 | 0.070 |
Why?
|
| Parathyroid Neoplasms | 1 | 2006 | 13 | 0.070 |
Why?
|
| Larynx | 1 | 2006 | 49 | 0.070 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2006 | 14 | 0.070 |
Why?
|
| Monitoring, Intraoperative | 1 | 2006 | 53 | 0.070 |
Why?
|
| Pressure | 1 | 2006 | 252 | 0.070 |
Why?
|
| Parathyroid Hormone | 1 | 2006 | 117 | 0.060 |
Why?
|
| Manometry | 1 | 2006 | 276 | 0.060 |
Why?
|
| Adenoma | 1 | 2006 | 132 | 0.060 |
Why?
|
| Laryngeal Diseases | 1 | 2005 | 22 | 0.060 |
Why?
|
| Quality of Health Care | 2 | 2018 | 322 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2004 | 2 | 0.060 |
Why?
|
| Neck Dissection | 2 | 2017 | 55 | 0.060 |
Why?
|
| Monitoring, Ambulatory | 1 | 2005 | 84 | 0.060 |
Why?
|
| Neck | 1 | 2004 | 62 | 0.060 |
Why?
|
| Parathyroid Diseases | 1 | 2003 | 1 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2006 | 403 | 0.060 |
Why?
|
| Hypercalcemia | 1 | 2003 | 34 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1745 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2006 | 1738 | 0.050 |
Why?
|
| Disease Progression | 1 | 2006 | 1038 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 104 | 0.050 |
Why?
|
| Esophagoscopy | 1 | 2021 | 72 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 66 | 0.050 |
Why?
|
| Tympanic Membrane Perforation | 1 | 2000 | 2 | 0.050 |
Why?
|
| Middle Ear Ventilation | 1 | 2000 | 7 | 0.050 |
Why?
|
| Otitis Media with Effusion | 1 | 2000 | 9 | 0.050 |
Why?
|
| Device Removal | 1 | 2000 | 100 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 114 | 0.040 |
Why?
|
| Operative Time | 1 | 2017 | 45 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2017 | 60 | 0.040 |
Why?
|
| Propensity Score | 1 | 2017 | 117 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 756 | 0.040 |
Why?
|
| Educational Status | 1 | 2017 | 273 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2017 | 201 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 281 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 319 | 0.030 |
Why?
|
| Medicaid | 1 | 2017 | 302 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2017 | 267 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 1851 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 201 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2013 | 45 | 0.030 |
Why?
|
| Palliative Care | 1 | 2014 | 271 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 2013 | 120 | 0.030 |
Why?
|
| Thyroiditis | 1 | 2011 | 5 | 0.030 |
Why?
|
| Electrocoagulation | 1 | 2010 | 35 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 249 | 0.020 |
Why?
|
| Mast Cells | 1 | 2010 | 113 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 442 | 0.020 |
Why?
|
| Recurrence | 2 | 2003 | 948 | 0.020 |
Why?
|
| Social Desirability | 1 | 2006 | 9 | 0.020 |
Why?
|
| Longevity | 1 | 2006 | 60 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2006 | 40 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2006 | 62 | 0.020 |
Why?
|
| Self Concept | 1 | 2006 | 132 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2006 | 91 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 2083 | 0.020 |
Why?
|
| Life Change Events | 1 | 2006 | 223 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2006 | 110 | 0.020 |
Why?
|
| Risk-Taking | 1 | 2006 | 210 | 0.020 |
Why?
|
| Catheterization | 1 | 2005 | 209 | 0.010 |
Why?
|
| Equipment Design | 1 | 2005 | 500 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 618 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2006 | 458 | 0.010 |
Why?
|
| Extremities | 1 | 2003 | 49 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2006 | 514 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 5300 | 0.010 |
Why?
|
| Algorithms | 1 | 2006 | 1196 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 365 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 2000 | 95 | 0.010 |
Why?
|
| Probability | 1 | 2000 | 245 | 0.010 |
Why?
|
| Depression | 1 | 2006 | 943 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2000 | 1330 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 20881 | 0.010 |
Why?
|